Internal FDA Fighting on Sarepta Bad Omen for Stem Cell Oversight?

Exondys-51-Sarepta-

The FDA caused major controversy by approving the drug Exondys 51 from Sarepta Therapeutics for treating Duchenne muscular dystrophy over the recommendations of a scientific panel it convened that had voted 7-3 against approval. Is this contentious Sarepta approval serve as a sign of how the FDA will deal with stem cells moving forward? Will the FDA approval, which …

Internal FDA Fighting on Sarepta Bad Omen for Stem Cell Oversight? Read More »